Biocon said that its wholly-owned subsidiary Biocon Biologics has received marketing approval for its pegfilgrastim biosimilar from Japan's Ministry of Health, Labour and Welfare (MHLW).
Market Samachar is a news aggregator. This article was originally published by Share Market Today. Tap the button above to read the full story on their site.